Acute myeloid leukemia News and Research RSS Feed - Acute myeloid leukemia News and Research

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. [More]
Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease. [More]
MRX-2843 treatment improves survival of acute myeloid leukemia patients

MRX-2843 treatment improves survival of acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, and several clinical trials are testing FLT3 inhibitors. [More]
Potential link between PLCD and ALL could offer new targets for cancer prevention research

Potential link between PLCD and ALL could offer new targets for cancer prevention research

A potential correlation between pre-labor cesarean delivery (PLCD) and acute lymphoblastic leukemia (ALL) could offer new targets for cancer prevention research, according to new research from the Masonic Cancer Center, University of Minnesota. [More]
EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML). [More]
IMP's Johannes Zuber receives German Cancer Prize 2016

IMP's Johannes Zuber receives German Cancer Prize 2016

Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research. [More]
Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML). [More]
Ohio State researchers working on new way to treat drug-resistant cancer

Ohio State researchers working on new way to treat drug-resistant cancer

Researchers at The Ohio State University are working on a new way to treat drug-resistant cancer that the ancient Greeks would approve of--only it's not a Trojan horse, but DNA that hides the invading force. [More]
Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. [More]
CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma Corp. today reported financial results for the fourth quarter and full year ended December 31, 2015. [More]
Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival. [More]
McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers have taken a giant leap in identifying the early stages of a deadly cancer and predicting how it will develop in individuals. [More]
Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. [More]
Researchers reveal inherited genetic errors across 12 cancer types

Researchers reveal inherited genetic errors across 12 cancer types

Researchers long have known that some portion of the risk of developing cancer is hereditary and that inherited genetic errors are very important in some tumors but much less so in others. [More]
Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers at Penn State College of Medicine, working with Chinese and American colleagues, have discovered a novel way to enhance and restore cancer suppressor activity in B-cell acute lymphoblastic leukemia, resulting in better outcomes in a pre-clinical model of the disease. The finding could pave the way for a new class of drugs for this and other forms of leukemia. [More]
Researchers find new significant link between NPM protein and development of AML

Researchers find new significant link between NPM protein and development of AML

A team of researchers from the National University of Singapore has found a new significant correlation between the protein nucleophosmin (NPM) and the development of an aggressive form of blood cancer called acute myeloid leukemia (AML). [More]
First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando. [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Scientists map out genes that keep cancer cells alive

Scientists map out genes that keep cancer cells alive

Scientists have mapped out the genes that keep our cells alive, creating a long-awaited foothold for understanding how our genome works and which genes are crucial in disease like cancer. [More]
Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. [More]
Advertisement
Advertisement